retatrutide clinical trial dose escalation Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Nearly 30% average weight loss

Some providers suggest extending the 2.5 mg phase to 8 weeks if the patient has significant weight to protect

The medication packaging is unmarked or damaged

Steady, continuous delivery Though injections provide better bioavailability than oral medication, bolus administration leads to a peak concentration of the drug in the bloodstream

There is currently no specific contraindication to using GLP-1 receptor agonists in people with Crohn's disease, but this decision requires careful individualised assessment

If you have been waiting to start weight management treatment because you are hoping for something with fewer side effects, eloralintide is not yet that option

doi: 10.1056/NEJMoa2206286 66 BhattDLSzarekMStegPGCannonCPLeiterLAMcGuireDKet al